Medicare Price Inflation Rebate List Revisions A Sign Of IRA Implementation Overload?
Executive Summary
The Centers for Medicare and Medicaid Services has a lot on its plate and is under intense stakeholder scrutiny as it implements the price control provisions of the Inflation Reduction Act.
You may also be interested in...
US FDA Rejects Melinta Effort To Go Beyond Court Order In FedEx-Driven ANDA Dispute
Court found FDA erred in finding Melinta received notice of Paragraph IV certification for generic Minocin on date specified by Nexus. Agency will not require Nexus to send a new notice or give Melinta heads up of final approval of the ANDA.
Medicare Part B Inflation Rebate List Doubles For Third Quarter, Adds Several Amgen Drugs
Amgen's Prolia appears to be the biggest drug on the list of products incurring price inflation penalties in Part B; many of the others have relatively low sales to Medicare.
Game On: Medicare Will Parry Manufacturer Efforts To Sidestep Price Negotiation, Guidance Says
CMS will need to continue to be ‘savvy’ to strategies brand manufacturers already employ to shape the landscape for generic and biosimilar competition, policy expert says.